Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
JDP2
(c-Jun dimerization protein 2) is a member of the basic leucine zipper family of transcription factors that is ubiquitously expressed in all examined cell types.
JDP2
is phosphorylated on Thr148 by JNK (c-Jun N-terminal kinase) and p38 kinase, although the functional role of its phosphorylation is unknown. In the present paper we show that the
JDP2
protein level is dramatically reduced in response to serum stimulation, anisomycin treatment, ultraviolet light irradiation and cycloheximide treatment, all of which activate the JNK pathway. In addition, endogenous and overexpressed
JDP2
are phosphorylated in response to these stimuli. Replacement of Thr148 with an alanine residue stabilizes ectopically expressed
JDP2
in the presence of the stimuli; conversely, substitution with glutamic acid destabilizes it. Serum-induced phosphorylation and degradation of
JDP2
are specific to JNK activation since a JNK inhibitor (SP600125) abolishes these effects, whereas p38 and
MEK
inhibitors (SB203580 and UO126) have no effect. In the presence of cycloheximide,
JDP2
is rapidly phosphorylated and degraded due to the combined effects of protein synthesis inhibition and activation of JNK. Pre-treatment of cells with SP600125 prior to cycloheximide treatment significantly prolongs the half-life of
JDP2
that is found mainly in the unphosphorylated form. Lastly, the proteasome inhibitor (MG132) rescues
JDP2
degradation following cycloheximide treatment and increases the expression of the
JDP2
phospho-mimetic T148E mutant. Collectively, these results suggest that phosphorylation of
JDP2
on thr148 by JNK targets it to the proteasome for degradation.
...
PMID:Phosphorylation of JDP2 on threonine-148 by the c-Jun N-terminal kinase targets it for proteosomal degradation. 2146 60
Extensive research has unraveled the molecular basis of learning processes underlying contextual fear conditioning, but the mechanisms of fear extinction remain less known. Contextual fear extinction occurs when an aversive stimulus that initially caused fear is no longer present and depends on the activation of the extracellular signal-regulated kinase (ERK), among other molecules. Here we investigated how ERK signaling triggered by extinction affects its downstream targets belonging to the activator protein-1 (AP-1) transcription factor family. We found that extinction, when compared to conditioning of fear, markedly enhanced the interactions of active, phospho-ERK (pERK ) with c-Jun causing alterations of its phosphorylation state. The AP-1 binding of c-Jun was decreased whereas AP-1 binding of JunD,
Jun dimerization protein 2
(
JDP2
) and ERK were significantly enhanced. The increased AP-1 binding of the inhibitory JunD and
JDP2
transcription factors was paralleled by decreased levels of the AP-1 regulated proteins c-Fos and GluR2. These changes were specific for extinction and were
MEK
-dependent. Overall, fear extinction involves ERK/Jun interactions and a decrease of a subset of AP-1-regulated proteins that are typically required for fear conditioning. Facilitating the formation of inhibitory AP-1 complexes may thus facilitate the reduction of fear.
...
PMID:ERK-associated changes of AP-1 proteins during fear extinction. 2146 87
Colony-stimulating factor 1 (CSF1) is known to promote osteoclast progenitor survival, but its roles in osteoclast differentiation and mature osteoclast function are less well understood. In a microarray screen,
Jun dimerization protein 2
(
JDP2
) was identified as significantly induced by CSF1. Recent reports indicate that
JDP2
is required for normal osteoclastogenesis and skeletal metabolism. Because there are no reports on the transcriptional regulation of this gene, the DNA sequence from -2612 to +682 bp (relative to the transcription start site) of the
JDP2
gene was cloned, and promoter activity was analyzed. The T box-binding element (TBE) between -191 and -141 bp was identified as the cis-element responsible for CSF1-dependent
JDP2
expression. Using degenerate PCR, Tbx3 was identified as the major isoform binding the TBE. Overexpression of Tbx3 induced
JDP2
promoter activity, whereas suppressing Tbx3 expression substantially attenuated CSF1-induced transcription. Suppressing Tbx3 in osteoclast precursors reduced
JDP2
expression and significantly impaired RANKL/CSF1-induced osteoclastogenesis. A
MEK1
/2-specific inhibitor was found to block CSF1-induced
JDP2
expression. Consistent with these data,
JDP2
(-/-) mice were found to have increased bone mass. In summary, CSF1 up-regulates
JDP2
expression by inducing Tbx3 binding to the
JDP2
promoter. The downstream signaling cascade from activated c-Fms involves the
MEK1
/2-ERK1/2 pathway. Tbx3 plays an important role in osteoclastogenesis at least in part by regulating CSF1-dependent expression of
JDP2
.
...
PMID:The transcription factor T-box 3 regulates colony-stimulating factor 1-dependent Jun dimerization protein 2 expression and plays an important role in osteoclastogenesis. 2439 18